Serum Pharmacokinetics in Patients Treated with Transarterial Chemoembolization (TACE) Using Two Types of Epirubicin-loaded Microspheres

The purpose of this study was the pharmacokinetic (PK) profile assessment in the serum of patients affected by hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) with drug-eluting beads. This study included 20 patients, 12 treated with DC Bead® and 8 with HepaSphere M...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2012-05, Vol.32 (5), p.1769-1774
Hauptverfasser:	SOTTANI, Cristina, POGGI, Guido, BERNARDO, Giovanni, MINOIA, Claudio, QUARETTI, Pietro, REGAZZI, Mario, MONTAGNA, Benedetta, QUAQUARINI, Erica, IMBRIANI, Marcello, LEONI, Emanuela, DI CESARE, Pamela, RICCARDI, Alberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibiotics, Antineoplastic - pharmacokinetics Biological and medical sciences Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Chemoembolization, Therapeutic Chromatography, High Pressure Liquid Epirubicin - administration & dosage Epirubicin - pharmacokinetics Female Gastroenterology. Liver. Pancreas. Abdomen Humans Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Microspheres Quality Control Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The purpose of this study was the pharmacokinetic (PK) profile assessment in the serum of patients affected by hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) with drug-eluting beads. This study included 20 patients, 12 treated with DC Bead® and 8 with HepaSphere Microsphere®, preloaded with epirubicin. No patient randomization was used for the inclusion in one group or in the other. Peripheral blood samples were obtained from all patients after the treatment, until 24 hours past the procedure. The pharmacokinetic study showed low peak serum epirubicin concentrations with greater drug exposure for the DC Bead® group (p
ISSN:	0250-7005 1791-7530